Search Results - leukemia

14 Results Sort By:
Covalent MEK4 Inhibitors for Targeted Cancer Therapy
NU 2025-154 INVENTORS Karl Scheidt* Gina Connors SHORT DESCRIPTION This technology introduces novel covalent inhibitors of MEK4, built upon previously-developed reversible inhibitors (see NU2019-059 and NU2021-217). A covalent inhibition strategy offers enhanced potency, selectivity, and prolonged duration of action compared to reversible...
Published: 12/16/2025   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Covalent Inhibition, Kinase Inhibitor, Leukemia, MEK4, MEK7, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Small Molecules that Inhibit RNA Binding Protein IGF2BP3 in Cancer (UCLA Case No. 2023-215)
UCLA researchers in the Department of Pathology and Laboratory Medicine have developed small molecules which inhibits the protein IGF2BP3, a highly expressed oncofetal protein in certain cancers, especially in B-acute lymphoblastic leukemia. BACKGROUND: Cancer remains the second leading cause of death in the U.S. Advancements in targeted therapies...
Published: 7/17/2025   |   Inventor(s): Dinesh Rao
Keywords(s): blood cancers, Cancer, cancer inhibition, leukemia
Category(s): Therapeutics > Oncology
Identification of a Factor That Rescues Dysregulated Endocytosis in Cultured Human Hematopoietic Stem Cells (UCLA Case No. 2023-051)
UCLA researchers in the Departments of Molecular, Cell & Developmental Biology have developed a novel method to enhance the function of hematopoietic stem cells (HSCs) to improve the transplantability of ex vivo expanded human HSCs in clinical settings. BACKGROUND: Hematopoietic stem cells (HSCs), present in blood and bone marrow, can form mature...
Published: 12/2/2025   |   Inventor(s): Hanna Mikkola, Julia Aguade Gorgorio
Keywords(s): bone marrow, bone marrow transplants, CRISPR, endocytosis, engraftment, environmental sensing, hematopoietic stem cells, leukemia, MLLT3, MYCT1, transplantability
Category(s): Therapeutics > Hematology, Life Science Research Tools, Therapeutics > Stem Cells And Regenerative Medicine
MEK7 inhibitors for acute lymphoblastic leukemia (ALL) treatment
NU 2023-060 INVENTORS Karl Scheidt* Dalton Kim Meghan Orr SHORT DESCRIPTION Rational design of highly potent and selective covalent MEK7 inhibitors BACKGROUND Acute lymphoblastic leukemia (ALL) is a deadly blood cancer, the most common hematological malignancy in patients under 14 years of age. Despite advancements in treatment, ALL relapse...
Published: 12/16/2025   |   Inventor(s):  
Keywords(s): ALL - Acute Lymphoblastic Leukemia, Cancer/Oncology, Leukemia, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Abstract: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after...
Published: 5/14/2025   |   Inventor(s): James Kochenderfer, Norris Lam
Keywords(s): act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Oncology
Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Abstract: CD19 and CD20 are promising targets for the treatment of B-Cell malignancies.  Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression...
Published: 5/14/2025   |   Inventor(s): James Kochenderfer, Shicheng Yang
Keywords(s): act, adoptive cell therapy, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia
Abstract: B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes.  Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST).  However, there is less than a 50% chance of finding a matching...
Published: 4/22/2025   |   Inventor(s): Christoph Rader, Sivasubramanian Baskar, Jessica Suschak, Ivan Samija, Michael Bishop
Keywords(s): alloHSCST, B-CELL, Leukemia, Lymphocytic
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Hybridoma cell line 715 expresses monoclonal antibody specific for Moloney murine leukemia virus (MuLV) gp70. Details may be found under NIH AIDS Reagent Program Catalog Number 1278: https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1278.aspx .
Published: 8/13/2025   |   Inventor(s): Bruce Chesebro
Keywords(s): 715, Cell, DDXXXX, Detect, Hybridoma, Leukemia, Line, Listed LPM Ano as of 4/15/2015, Mab, moloney, Murine, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, virus, VLXXXX, WIXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials
Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80
Hybridoma cell line 500 expresses monoclonal antibody specific for Moloney murine leukemia virus (MuLV) gp80. Details may be found under NIH AIDS Reagent Program Catalog Number 1277: https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1277.aspx .
Published: 8/13/2025   |   Inventor(s): Bruce Chesebro
Keywords(s): 500, Cell, DDXXXX, Detect, Hybridoma, Leukemia, Line, Listed LPM Ano as of 4/15/2015, Mab, moloney, Murine, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, virus, VLXXXX, WIXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials
Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Hybridoma cell line 273 expresses monoclonal antibody specific for murine leukemia virus (MuLV) gp70. Details may be found under NIH AIDS Reagent Program Catalog Number 1279: https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1279.aspx .
Published: 8/13/2025   |   Inventor(s): Bruce Chesebro
Keywords(s): 273, Cell, DDXXXX, Detect, Hybridoma, Leukemia, Line, Listed LPM Ano as of 4/15/2015, Mab, moloney, Murine, NIH ARP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, virus, VLXXXX, WIXXXX
Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Infectious Disease
1 2